Levco Pharmaceuticals

Levco Pharmaceuticals is an Israel-based biotechnology company focused on developing novel liposomal dual-drug products for cancer treatment. Established in 2020 as a subsidiary of Rafael Holdings, the company leverages advanced pegylated liposome technology to co-encapsulate two active pharmaceutical ingredients within a single delivery vehicle. Its lead research involves the combination of doxorubicin and alendronate (PLAD) for the treatment of soft tissue sarcomas. The company's approach aims to enhance the chemo-immunotherapeutic effects of established drugs through targeted delivery and improved pharmacokinetics. While Rafael Holdings curtailed material investment in the company in 2022 to focus on other assets, Levco remains a majority-owned subsidiary within its portfolio.